Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Atractylenolide I is a sesquiterpene that has been found in the rhizomes of A. macrocephala and has diverse biological activities, including anti-inflammatory, anti-angiogenic, anti-tumor, and antidepressant properties.1,2,3,4 It inhibits LPS-induced increases in TNF-α and nitric oxide (NO) production, as well as inducible nitric oxide synthase (iNOS) activity, in murine peritoneal macrophages (IC50s = 23.1, 41, and 67.3 μM, respectively).1 Atractylenolide I reduces pouch fluid weight, inflammatory cell count, granuloma weight, and vascular index (ID50s = 24.18, 19.46, 14.44, and 15.15 mg/kg, respectively) in a mouse air pouch granuloma model induced by Freund's complete adjuvant (FCA).2 It also reduces the number of microvessels in the air pouch wall by 58.27% when administered at a dose of 20 mg/kg and reduces the blood levels of TNF-α, IL-1β, IL-6, VEGF, placenta growth factor (PlGF), and bFGF in a dose-dependent manner in a mouse model of FCA-induced granuloma. Atractylenolide I inhibits the growth of T-24, 5637, RT4, and 253J bladder cancer cells in vitro (IC50s = 12.8-63.7 μM) and reduces tumor growth in T-24 and 253J mouse xenograft models in a dose-dependent manner.3 In a mouse model of depression induced by chronic unpredictable mild stress, atractylenolide I reverses stress-induced decreases in hippocampal levels of serotonin (5-HT; Item No. 14332) and norepinephrine (Item No. 16673) and reduces immobility time in the forced swim and tail suspension tests in a dose-dependent manner, indicating antidepressant-like activity.4
WARNING This product is not for human or veterinary use.
1. Atractylenolide I and atractylenolide III inhibit Lipopolysaccharide-
2. Inhibitory effect of atractylenolide I on angiogenesis in chronic inflammation in vivo and in vitro. Eur. J. Pharmacol. 612(1-3), 143-152 (2009).
3. Anti-
4. Anti-